Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMemphasys Ltd

Memphasys Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.004 AUD 0.00(0%)
Last update at 2026-11-12T04:06:00Z
VOLUME
1746734
Market Cap
12.38M

Momentum Score

…

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Memphasys Ltd develops a microfluidic, electrophoretic sperm separation system for use in assisted reproduction to reduce sperm damage from centrifugation. Long-term growth may be supported by rising demand for assisted reproductive technologies, regulatory approvals and commercial partnerships that could scale device and consumable sales while addressing a clear clinical need.

Key risks include early-stage commercialisation with limited sales and clinical/regulatory track record, adoption competition from established methods and possible need for additional capital.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.66M
Revenue Per Share
-
Gross Profit TTM
0.36M
Debt / Equity
1.01
ROE
-95.94%
Net Debt
3.07M
ROCE
-98.48%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4.10M -4.94M -4.44M -3.40M -2.08M
Net income -4.10M -4.94M -4.44M -3.40M -2.08M
Selling general administrative - 0.86M 1.25M 0.58M 1.09M
Selling and marketing expenses - 0.09M 0.11M 0.15M 0.11M
Gross profit -1.52M 0.43M -1.57M 0.01M 0.01M
Reconciled depreciation - - 0.72M 0.61M 0.12M
Ebit -4.15M -3.23M -4.95M -3.09M -1.63M
Ebitda -3.56M -2.57M -4.24M -2.47M -1.51M
Depreciation and amortization 0.59M 0.67M 0.72M 0.61M 0.12M
Operating income -4.15M -2.57M -5.24M -2.76M -1.97M
Other operating expenses 4.43M 3.09M 5.30M 3.60M 2.05M
Interest expense 0.38M 0.59M 0.42M 0.32M 0.45M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.58M 0.31M 0.39M 0.00M
Net interest income - - -0.42M -0.41M -0.57M
Income tax expense - - 0.00M 0.96M 1.67M
Total revenue 0.27M 0.53M 0.06M 0.02M 0.03M
Total operating expenses 2.63M 3.00M 3.68M 3.64M 2.74M
Cost of revenue 1.80M 0.10M 1.63M 0.01M 0.02M
Total other income expense net 0.05M -2.38M 0.80M 0.65M 1.22M
Net income from continuing ops - - -4.44M -3.40M -2.08M
Net income applicable to common shares - -5.04M -4.44M -3.40M -2.08M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 11.24M 11.02M 12.43M 14.67M 14.12M
Intangible assets 8.80M 9.11M - 10.29M 9.68M
Other current assets 0.31M 0.08M 1.18M 1.36M 1.55M
Total liab 7.02M 5.65M 5.59M 7.28M 6.47M
Total stockholder equity 4.21M 5.37M 6.84M 7.38M 7.65M
Other current liab 1.39M 0.26M 0.24M 5.45M 4.41M
Common stock 64.51M 60.61M 57.28M 53.42M 50.34M
Capital stock - - - 53.42M 50.34M
Retained earnings -60.38M -55.25M -50.43M -46.17M -42.77M
Other liab - - - 0.00M 0.03M
Cash 1.18M 0.30M 0.28M 0.64M 0.27M
Total current liabilities 7.02M 5.38M 5.25M 5.57M 4.54M
Current deferred revenue - - 0.07M -4.66M -3.66M
Net debt 3.07M 4.81M 4.48M 5.73M 5.29M
Short term debt 4.24M 4.83M 4.42M 4.66M 3.66M
Short long term debt - - - 4.55M 3.56M
Short long term debt total 4.24M 5.11M 4.76M 6.37M 5.56M
Other stockholder equity - - -0.01M -7.24M -7.57M
Property plant equipment - - - 2.10M 2.34M
Total current assets 2.20M 1.33M 1.62M 2.25M 2.03M
Long term investments - - - 0.03M 0.07M
Net tangible assets - - - -2.91M -2.03M
Short term investments - - - 0.04M -
Net receivables 0.55M 0.90M - 0.12M 0.12M
Long term debt - - - - 0.08M
Inventory 0.17M 0.06M 0.16M 0.13M 0.09M
Accounts payable 1.38M 0.28M 0.52M 0.12M 0.13M
Accumulated other comprehensive income 0.08M 0.00M - 0.14M 0.08M
Non currrent assets other - - 10.09M -12.42M -12.09M
Non current assets total 9.03M 9.69M 10.81M 12.42M 12.09M
Capital lease obligations - - - 1.83M 1.92M
Long term debt total - - - 1.71M 1.83M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -0.71M -1.98M -3.08M
Change to liabilities - - - -0.00M 1.89M
Total cashflows from investing activities -0.00M -0.67M -0.71M -1.98M -3.08M
Net borrowings - - 0.29M 0.68M -0.01M
Total cash from financing activities 3.37M 3.15M 3.54M 3.75M 1.03M
Change to operating activities - - - 1.93M 0.86M
Net income -4.10M -4.94M -4.44M -3.40M -2.08M
Change in cash 0.88M 0.06M -0.40M 0.37M -1.73M
Begin period cash flow 0.30M 0.24M 0.64M 0.27M 2.00M
End period cash flow 1.18M 0.30M 0.24M 0.64M 0.27M
Total cash from operating activities -2.49M -2.41M -3.23M -1.41M -0.37M
Issuance of capital stock - - 3.72M 3.36M 1.08M
Depreciation 0.59M 0.67M 0.72M 0.12M 0.12M
Other cashflows from investing activities - -0.67M -0.08M -0.15M -0.15M
Dividends paid - - - 0.85M 0.07M
Change to inventory -0.11M 0.11M -0.03M -0.04M 0.03M
Change to account receivables 0.35M -0.01M 0.65M - -
Sale purchase of stock - 3.73M -0.37M -0.28M -0.03M
Other cashflows from financing activities - -0.16M -0.10M 1.60M -0.01M
Change to netincome - - - -0.50M -0.55M
Capital expenditures 0.00M 0.00M 0.64M 1.82M 2.92M
Change in working capital 1.32M 0.91M 1.65M -0.04M 0.03M
Stock based compensation - - 0.04M 0.09M 0.07M
Other non cash items -0.30M 0.96M -1.20M 1.88M 1.59M
Free cash flow -2.49M -2.41M -3.87M -3.23M -3.29M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MEM
Memphasys Ltd		 -
-%		 0.00 - - 18.82 2.94 56.37 -11.16
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Memphasys Ltd

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

34-36 Richmond Road, Homebush, NSW, Australia, 2140

61 2 8415 7300

https://www.memphasys.com

Name Title Year Born
Ms. Alison Mary Coutts B.E., B.E. (Chem), GDipBiotech, M.B.A., MBA MD, CEO & Director NA
Pablo Neyertz Director of Fin. NA
Nick Gorring Operations Mang. NA
Mr. Malcolm Coleman Chief Financial Officer of Nusep Ltd NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Sec. NA
Dr. David Ali Acting CEO & Executive Director NA
Pablo Neyertz Director of Finance NA
Associate Prof. Hassan Bakos Director of Operations NA
Prof. R. John Aitken Ph.D., ScD FRSE Scientific Director NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…